Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: A review

Journal of Sex and Marital Therapy

Volumn 38, Issue 3, 2012, Pages 281-301

  Nunes, Luciana Vargas Alves ^a,b   Moreira, Hugo Cogo ^b   Razzouk, Denise ^b   Nunes, Sandra Odebrecht Vargas ^a   Mari, Jair De Jesus ^b  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; QUINOLONE DERIVATIVE; SILDENAFIL; SULFONE; VASODILATOR AGENT;

ADULT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG SUBSTITUTION; ERECTILE DYSFUNCTION; FEMALE; HUMAN; HYPERPROLACTINEMIA; MALE; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; PIPERAZINES; PSYCHOTIC DISORDERS; PURINES; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SULFONES; VASODILATOR AGENTS;

EID: 84861307668     PISSN: 0092623X     EISSN: 15210715     Source Type: Journal    
DOI: 10.1080/0092623X.2011.606883     Document Type: Review

References (63)

1. Aizenberg, D., Modai, I., Landa, A., Gil-Ad, I., & Weizman, A. (2001). Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. Journal of Clinical Psychiatry, 62, 541-544. (Pubitemid 32703094)
2. Aizenberg, D., Shiloh, R., Zemishlany, Z., & Weizman, A. (1996). Low-dose imipramine for thioridazine-induced male orgasmic disorder. Journal of Sex & Marital Therapy, 22, 225-229. (Pubitemid 26314108)
3. Atmaca, M., Kuloglu, M., & Tezcan, E. (2002). Sildenafil use in patients with olanzapine-induced erectile dysfunction. International Journal of Impotence Research, 14, 547-549. (Pubitemid 36068438)
4. Aviv, A., Shelef, A., & Weizman, A. (2004). An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. Journal of Clinical Psychiatry, 65(1), 97-103.
5. Beau, Y., & Guillard, P. (1980). Essai de traitement par la bromocriptine des effets secondaires endocriniens des traitements psychotropes [Trial therapy with bromocriptine of secondary endocrine effects after psychotropic treatment]. Annales Medico-Psychologiques, 138, 179-186. (Pubitemid 10091873)
6. Berner, M., Hagen, M., & Kriston, L. (2006). A systematic review of research on strategies for the management of antipsychotic-induced sexual dysfunction: High level evidence is needed. Journal of Clinical Psychiatry, 67, 1649-1650. (Pubitemid 44787451)
7. Berner, M., Hagen, M., & Kriston, L. (2007). Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database of Systematic Reviews, 1. doi: 10.1002/14651858.CD003546.pub2. (Pubitemid 351820492)
8. Bobes, J., Garcia-Portilla, M. P., Rejas, J., Hernandez, G., Garcia-Garcia, M., Rico-Villademoros, F., & Porras, A. (2003). Frequency of sexual dysfunction and other reproductive side effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol. Journal of Sex & Marital Therapy, 29, 125-147. (Pubitemid 36278732)
9. Byerly, M., Lescouflair, E., Weber, M. T., Bugno, R. M., Fisher R., Carmody, T., . . . Rush, A. J. (2004). An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. Journal of Sex & Marital Therapy, 30, 325-332. (Pubitemid 39304859)
10. Byerly, M., Marcus, R. N., Tran, Q. V., Eudicone, J. M., Whitehead, R., & Baker, R. A. (2009). Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study. Schizophrenia Research, 107, 218-222.
11. Byerly, M., Nakonezny, P., Bettcher, B., Carmody, T., Fisher, R., & Rush, A. J. (2006). Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophrenia Research, 86, 244-250. (Pubitemid 44234038)
12. Byerly, M., Nakonezny, P., & Rush, A. J. (2008). Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind pilot trial. Psychiatry Research, 159, 115-120.
13. Cavallaro, R., Cocchi, F., Angelone, S. M., Lattuada, E., & Smeraldi, E. (2004). Cabergoline treatment of risperidone-induced hyperprolactinemia: A pilot study. Journal of Clinical Psychiatry, 65, 1429-1431.
14. Chen, J. X., Su, Y. A., Wang, S. L., Bian, Q. T., Liu, Y. H., Wang, N., . . . Zhang, X. Y. (2009). Aripiprazole treatment of risperidone-induced hyperprolactinemia. Journal of Clinical Psychiatry, 70, 1058-1059.
15. Correa, N., Opler, L. A., Kay, S. R., & Birmasher, B. (1987). Amantadine in the treatment of neuroendocrine side effects of neuroleptics. Journal of Clinical Psychopharmacology, 7(2), 91-95. (Pubitemid 17053370)
16. Costa, A. M. N., Lima, M. S., Faria, M., Filho, S. R., Oliveira, I. R., Mari, J. J. (2007). A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. Psychopharmacology, 21, 165-170. (Pubitemid 46280467)
17. Costa, A. M. N., Lima, M. S., & Mari, J. J. (2006). A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. São Paulo Medical Journal, 124, 291-297. (Pubitemid 46210378)
18. Cutler, A. J. (2003). Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology, 28, 69-82. (Pubitemid 36015662)
19. Gonzalez, A. L. M., Villademoros, R., & Tafalla, M. (2005). A 6-month prospective observational study on the effects of quetiapine on sexual functioning. Journal of Clinical Psychopharmacology, 25, 533-538. (Pubitemid 41669044)
20. Gopalakrishnan, R., Jacob, K. S., Kuruvilla, A., Vasantharaj, B., & John, J. K. (2006). Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: A randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. The American Journal of Psychiatry, 163, 494-499. (Pubitemid 44469393)
21. Haddad, P. M., & Sharma, S. G. (2007). Adverse effects of atypical antipsychotics. CNS Drugs, 21, 911-936.
22. Haddad, P. M., & Wieck, A. (2004). Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs, 64, 2291-2314. (Pubitemid 39388605)
23. Haro, J. M., & Carulla, L. S. (2006). The SOHO (Schizophrenia Outpatient Health Outcome) study: Implications for the treatment of schizophrenia. CNS Drugs, 20, 293-301.
24. Heald, A. (2010). Physical health in schizophrenia: A challenge for antipsychotic therapy. European Psychiatry, 25, S6-S11.
25. Heald, A., Montejo, A. L., Millar, H., De Hert, M., McCrae, J., & Correll, C. U. (2010). Management of physical health in patients with schizophrenia: practical recommendations. European Psychiatry, 25, S41-S45.
26. Ishitobi, M., Kosaka, H., Shukunami, K., Murata, T., & Wada, Y. (2010). Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 34, 1361-1362.
27. Kane, J. M., Meltzer, H. Y., Carson, W. H., McQuade, R. D., Marcus, R. N., & Sanchez, R. (2007). Aripiprazole for treatment resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study versus fluphenazine. Journal of Clinical Psychiatry, 68, 213-223.
28. Kaneda, Y., Kawamura, I., Fujii, A., & Ohmori, T. (2004). Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia. Neuroendocrinology Letters, 25(1-2), 35-40.
29. Kelly, D. L., & Conley, R. R. (2006). A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology, 31, 340-346. (Pubitemid 43261653)
30. Kim, K. S., Pae, C. U., Chae, J. H., Bahk, W. M., Jun, T. Y., Kim, D. J., & Dickson, R. A. (2002). Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. Journal of Clinical Psychiatry, 63, 408-413. (Pubitemid 34507218)
31. Kinon, B. J., Ahl, J., Liu-Seifert, H., & Maguire, G. A. (2006). Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology, 31, 577-588.
32. Knegtering, H., van den Bosch, R., Castelein, S., Bruggeman, R., Sytema, S., & van Os, J. (2008). Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology, 33, 711-717.
33. Kodesh, A., Weizman, A., Aizenberg, D., Hermesh, H., Gelkopf, M., & Zemishlany, Z. (2003). Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: A pilot study. Clinical Neuropharmacology, 26, 193-195. (Pubitemid 36951064)
34. Lambert, M., Conus, P., Eide, P., Mass, R., Karow, A., & Moritz, S. (2004). Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. European Psychiatry, 19, 415-422. (Pubitemid 39422495)
35. Lambert, M., Haro, J. M., Novik, D., Edgell, E., Kennedy, L., Ratcliffe, M., & Naber, D. (2005). Olanzapine vs other antipsychotics in actual out-patient settings: Six months tolerability results from the European schizophrenia outpatient health outcomes study. Acta Neuropsychiatrica Scandinavica, 111, 232-243. (Pubitemid 40342192)
36. Laumann, E. O., Paik, A., & Posen, R. C. (1999). Sexual dysfunction in the United States: Prevalence and predictors. JAMA, 281, 537-554.
37. Lee, B. H., Kim, Y. K., & Park, S. H. (2006). Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study. Progress in Neuro-Psychopharmacology and Biological, 30, 714-717.
38. Lee, H. S., Song, D. H., Kim, J. H., Lee, Y. M., Han, E. S., & Yoo, K. J. (1995).Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: A double-blind placebo-controlled study. International Clinical Psychopharmacology, 10(2), 67-72.
39. Lin, C. Y., Wu, P. L., Pariante, C. M., & Su, K. P. (2006). A crossover study of prolactin changes associated with risperidone and olanzapine. Journal of Clinical Psychiatry, 67, 1470-1471. (Pubitemid 44583398)
40. Lu, M. L., Shen, W. W., & Chen, C. H. (2008). Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Progress in Neuro-Psychopharmacology and Biological, 32, 1978-1981.
41. MacDonald, S., Halliday, J., MacEvan, T., Sharkey, V., Farrington, S., Wall, S., & McCreadie, R. G. (2003). Nithsdale Schizophrenia Surveys 24: Sexual dysfunction: Case-control study. The British Journal of Psychiatry, 182, 50-56. (Pubitemid 36132419)
42. Matsuoka, I., Nakai, T., Miyake, M., Hirai, M., & Ikawa, G. (1986). Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. Journal of Psychiatry & Neurology, 40, 639-646. (Pubitemid 17050624)
43. Mir, A., Shivakumar, K., Williamson, R. J., McAllister, V., O'Keane, V., & Aitchison, K. J. (2008). Change in sexual dysfunction with aripiprazole: A switching or add-on study. Journal of Psychopharmacology, 22, 244-253. (Pubitemid 351847447)
44. Mitsonis, C. I., Mitropoulos, P. A., Dimopoulos, N. P., Kararizou, E. G., Psarra, V. V., Tsakiris, F. E., & Katsanou, M. N. (2008). Vardenafil in the treatment of erectile dysfunction in outpatients with chronic schizophrenia: A flexible-dose, open-label study. Journal of Clinical Psychiatry, 69, 206-212. (Pubitemid 351469263)
45. Montejo, A. L., & Rico-Villademoros, F. (2008). Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: A 3-month prospective, observational study. Journal of Clinical Psychopharmacology, 28, 568-570.
46. Nakajima, M., Terao, T., Iwata, N., & Nakamura, J. (2005). Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: Effects on hyperprolactinemia. Pharmacopsychiatry, 38(1), 17-19. (Pubitemid 40278641)
47. Nakonezny, P. A., Byerly, M. J., & Rush, A. J. (2007). The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind trial of risperidone vs. quetiapine. Journal of Sex & Marital Therapy, 33, 203-216. (Pubitemid 46535723)
48. Olfson, M., Uttaro, T., Carson, W. H., & Tafesse, E. (2005). Male sexual dysfunction and quality of life in Schizophrenia. Journal of Clinical Psychiatry, 66, 331-338. (Pubitemid 40476756)
49. Peuskens, J., Sienaert, P., & De Hert, M. (1998). Sexual dysfunction: The unspoken side effects of antipsychotics. European Psychiatry, 13(Suppl. 1), 23-30.
50. Rosenberg, K. P., Bleiberg, K. L., Koscis, J., & Gross, C. (2003). A survey of sexual side effects among severely mental ill patients taking psychotropic medication: Impact on compliance. Journal of Sex & Marital Therapy, 29, 289-296. (Pubitemid 36807936)
51. Shim, J. C., Kelly, D. L., Jung, D. U., Seo, Y. S., Liu, K. H., Shon, J. H., & Conley, R. R. (2007). Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. The American Journal of Psychiatry, 164(9), 1404-1410. (Pubitemid 47461141)
52. Tharyan, P., & Gopalakrishan, G. (2006). Erectile dysfunction. BMJ Clinical Evidence, 15, 1227-1251.
53. Uçok, A., Incesu, C., Aker, T., & Erkoç, S. (2007). Sexual dysfunction in patients with schizophrenia on antipsychotic medication. European Psychiatry, 22, 328-333. (Pubitemid 47088198)
54. Uçok, A., Incesu, C., Aker, T., & Erkoc, S. (2008). Do psychiatrists examine sexual dysfunction in schizophrenia patients? Journal of Sexual Medicine, 5, 2000-2001.
55. Valevski, A., Modai, I., Zbarski, E., Zemishlany, Z., & Weizman, A. (1998). Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients. Clinical Neuropharmacology, 21, 355-357. (Pubitemid 28543952)
56. Van Bruggen, M., Amelsvoort, T., Wouters, L., Dingemans, P., Haan, L., & Linszen, D. (2009). Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology, 34, 989-995.
57. Volavka, J., Czobor, P., Cooper, T. B., Sheitman, B., Lindenmayer, J. P., Citrome, L., & Lieberman, J. A. (2004). Prolactin levels in schizophrenia and schizoaffective disorders patients treated with clozapine, olanzapine, risperidone, or haloperidol. Journal of Clinical Psychiatry, 65, 57-61.
58. Wehring, H., & Kelly, D. L. (2009). Sexual dysfunction and schizophrenia. In J. M. Meyer & H. D. Nasrallah (Eds.), Medical illness and schizophrenia (2nd ed., pp. 303-342). Washington, DC: American Psychiatric Publishing.
59. Weiden, P. J., Daniel, D. G., Simpson, G. R., & Steven J. (2003). Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. Journal of Clinical Psychopharmacology, 23, 595-600. (Pubitemid 37443191)
60. Yamada, K., Kanba, S., Yagi, G., & Asai, M. (1997). Effectiveness of herbal medicine (Shakuyaku-kanzo-to) for neuroleptic-induced hyperprolactinemia. Journal of Clinical Psychopharmacology, 17, 234-235. (Pubitemid 27261788)
61. Yasui-Furukori, N., Furukori, H., Sugawara, N., Fujii, A., & Kaneko, S. (2010). Dosedependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. Journal of Clinical Psychopharmacology, 30, 596-599.
62. Yuan, H. N., Wang, C. Y., Sze, C. W., Tong, Y., Tan, Q. R., Feng, X. J., Zhang, Z. J. (2008). A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Journal of Clinical Psychopharmacology, 28, 264-370.
63. Zemishlany, Z., & Weizman, A. (2008). The impact of mental illness on sexual dysfunction. Advances in Psychosomatic Medicine, 29, 89-106